CLO21-018: Clinical Characteristics of Breast Cancer Patients Treated With Trastuzumab-anns, a Trastuzumab Biosimilar, in a Real-World Setting

Reshma Mahtani; Ran Jin; Neil Accortt; Darcier Sandschafe; Tatiana Lawrence

CLO21-018: Clinical Characteristics of Breast Cancer Patients Treated With Trastuzumab-anns, a Trastuzumab Biosimilar, in a Real-World Setting

Reshma Mahtani
, Ran Jin
, Neil Accortt
, Darcier Sandschafe
, Tatiana Lawrence

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of The National Comprehensive Cancer Network
Volume	19
State	Published - Mar 3 2021

Disciplines

Medicine and Health Sciences

Cite this

@article{a3fe1d9c489340cc9b73b7b23f9a81d2,

title = "CLO21-018: Clinical Characteristics of Breast Cancer Patients Treated With Trastuzumab-anns, a Trastuzumab Biosimilar, in a Real-World Setting",

author = "Reshma Mahtani and Ran Jin and Neil Accortt and Darcier Sandschafe and Tatiana Lawrence",

note = "Background: Trastuzumab-anns was launched in the US in July 2019 as the first trastuzumab biosimilar for treating human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer (BC) and metastatic gastric cancer. Information on how trastuzumab-anns is being used in clinical practice is beginning to evolve.",

year = "2021",

month = mar,

day = "3",

language = "American English",

volume = "19",

journal = "Journal of The National Comprehensive Cancer Network",

}

TY - JOUR

T1 - CLO21-018: Clinical Characteristics of Breast Cancer Patients Treated With Trastuzumab-anns, a Trastuzumab Biosimilar, in a Real-World Setting

AU - Mahtani, Reshma

AU - Jin, Ran

AU - Accortt, Neil

AU - Sandschafe, Darcier

AU - Lawrence, Tatiana

N1 - Background: Trastuzumab-anns was launched in the US in July 2019 as the first trastuzumab biosimilar for treating human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer (BC) and metastatic gastric cancer. Information on how trastuzumab-anns is being used in clinical practice is beginning to evolve.

PY - 2021/3/3

Y1 - 2021/3/3

UR - https://doi.org/10.6004/jnccn.2020.7767

M3 - Article

VL - 19

JO - Journal of The National Comprehensive Cancer Network

JF - Journal of The National Comprehensive Cancer Network

ER -

CLO21-018: Clinical Characteristics of Breast Cancer Patients Treated With Trastuzumab-anns, a Trastuzumab Biosimilar, in a Real-World Setting

Disciplines

Other files and links

Cite this